Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
107Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $59.62M | $8.57M | $0.15 |
| 2024 | $47.98M | $-68.57M | $-1.27 |
| 2023 | $103.78M | $22.81M | $0.43 |
| 2022 | $48.58M | $-46.41M | $-1.23 |
| 2021 | $3.07M | $-89.76M | $-2.91 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.16 per share
Typical surprise +48.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.16 vs $-0.17beat
- Wed, May 13$-0.13 vs $-0.18beat
- Thu, Mar 26$0.53 vs $-0.20beat
- Thu, Nov 13$-0.13 vs $-0.25beat
- Tue, Aug 12$-0.03 vs $-0.38beat
- Tue, May 13$-0.25 vs $-0.55beat
Estimates and results for SPRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.22
- Implied price
- $3.60
- Return from $1.23
- 23.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.79 — today's price is already 31.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | 6.2% | 9.5% | 12.5% | 15.1% | 17.6% |
| 3.0% | 11.6% | 15.1% | 18.2% | 21.0% | 23.6% |
| 8.0% | 17.0% | 20.7% | 23.9% | 26.9% | 29.6% |
| 13.0% | 22.4% | 26.3% | 29.7% | 32.8% | 35.6% |
| 18.0% | 27.8% | 31.8% | 35.4% | 38.6% | 41.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- Newsseekingalpha.com·2d ago·Positive
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Neutral
Spero Therapeutics Q2 Earnings Call Highlights Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗